chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027435:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027435:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: Baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:Same reporter US-GSK-US2024AMR027435:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027435:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027434:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: Baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027435:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027448:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027435:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027435:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027448:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027435:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027435:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027448:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027435:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027435:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:SAME REPORTER US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027435:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027435:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027441:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027435:Same reporter
Sex: U
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: baby patient received Arexvy vaccine; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a infant patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: baby patient received Arexvy vaccine). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 22-FEB-2024 The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, the vaccine was administered to 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 25 babies received incorrect vaccines. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The 25 patients received Arexvy vaccine below the recommended age schedule, which led to inappropriate age at vaccine administration. This case was 1 of 25 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:Same reporter US-GSK-US2024AMR027429:Same reporter US-GSK-US2024AMR027430:Same reporter US-GSK-US2024AMR027431:Same reporter US-GSK-US2024AMR027432:Same reporter US-GSK-US2024AMR027433:Same reporter US-GSK-US2024AMR027434:Same reporter US-GSK-US2024AMR027448:Same reporter US-GSK-US2024AMR027436:Same reporter US-GSK-US2024AMR027437:Same reporter US-GSK-US2024AMR027438:Same reporter US-GSK-US2024AMR027439:Same reporter US-GSK-US2024AMR027440:Same reporter US-GSK-US2024AMR027335:Same reporter US-GSK-US2024AMR027442:Same reporter US-GSK-US2024AMR027443:Same reporter US-GSK-US2024AMR027444:Same reporter US-GSK-US2024AMR027445:Same reporter US-GSK-US2024AMR027446:Same reporter US-GSK-US2024AMR027447:Same reporter US-GSK-US2024AMR027428:Same reporter US-GSK-US2024AMR027427:Same reporter US-GSK-US2024AMR027426:Same reporter US-GSK-US2024AMR027435:Same reporter